文章：

淋巴克隆性造血：对恶性肿瘤、免疫及治疗的影响

Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment

原文发布日期：2023-01-04

DOI: 10.1038/s41408-022-00773-8

类型: Review Article

开放获取: 是

英文摘要：

Clonal hematopoiesis (CH) is the age-related expansion of hematopoietic stem cell clones caused by the acquisition of somatic point mutations or mosaic chromosomal alterations (mCAs). Clonal hematopoiesis caused by somatic mutations has primarily been associated with increased risk of myeloid malignancies, while mCAs have been associated with increased risk of lymphoid malignancies. A recent study by Niroula et al. challenged this paradigm by finding a distinct subset of somatic mutations and mCAs that are associated with increased risk of lymphoid malignancy. CH driven by these mutations is termed lymphoid clonal hematopoiesis (L-CH). Unlike myeloid clonal hematopoiesis (M-CH), L-CH has the potential to originate at both stem cells and partially or fully differentiated progeny stages of maturation. In this review, we explore the definition of L-CH in the context of lymphocyte maturation and lymphoid malignancy precursor disorders, the evidence for L-CH in late-onset autoimmunity and immunodeficiency, and the development of therapy-related L-CH following chemotherapy or hematopoietic stem cell transplantation.
 

摘要翻译： 

克隆性造血是指随着年龄增长，由于获得性体细胞点突变或嵌合染色体改变而引起的造血干细胞克隆扩增。由体细胞突变引起的克隆性造血主要与髓系恶性肿瘤风险增加相关，而嵌合染色体改变则与淋巴系统恶性肿瘤风险升高有关。近期Niroula等人的研究打破了这一传统认知，他们发现特定类型的体细胞突变和嵌合染色体改变与淋巴系统恶性肿瘤风险上升存在关联。这类突变驱动的克隆性造血被定义为淋巴系克隆性造血。与髓系克隆性造血不同，淋巴系克隆性造血可能起源于干细胞阶段，也可能发生在部分或完全分化的子代细胞成熟阶段。本综述将围绕淋巴细胞成熟与淋巴瘤前驱病变的背景下探讨淋巴系克隆性造血的定义，分析迟发自免疫缺陷及自身免疫疾病中淋巴系克隆性造血的证据，并阐述化疗或造血干细胞移植后治疗相关淋巴系克隆性造血的发展进程。

原文链接：

Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment